Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A)

Stroke

Volumn 29, Issue 3, 1998, Pages 577-580

  Longstreth Jr , W T ^a,b,d   Rosendaal, F R ^c   Siscovick, D S ^a,b   Vos, H L ^c   Schwartz, S M ^a,b   Psaty, B M ^a,b   Raghunathan, T E ^a,b   Koepsell, T D ^a,b   Reitsma, P H ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cerebrovascular disorders; Factor V; Mutation; Prothrombin

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SCREENING; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOPHILIA; THROMBOSIS;

EID: 0344765521     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.3.577     Document Type: Article

References (47)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
4. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997;98:353-355.
5. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89:2817-2821.
6. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
7. Bentolila S, Ripoll L, Drouet L, Mazoyer E, Woimant F. Thrombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young. Stroke. 1997;28:1846-1847. Letter.
8. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost. 1994;72:647. Letter.
9. Halbmayer W-M, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994;5:51-57.
10. Bachmeyer C, Toulon P, Dhote R, Christoforov B, Zuber M, Mas J-L. Ischemic stroke and activated protein C resistance. JAMA. 1995;274:1266. Letter.
11. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783-785.
12. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet. 1995;345:795. Letter.
13. Kontula K, Ylikorkala A, Miettinen H, Vuono A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost. 1995;73:558-560.
14. Lalouschek W, Suess E, Aull S, Schruder P, Uhl F, Zeiler K, Pabinger-Fasching I. Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke. Stroke. 1995;26:1963-1964. Letter.
15. Lellouche F, Dorval I, Dewilde J, van Walleghem E. Presence of G1691A mutation on the gene of factor V in arterial thrombosis. Presse Med. 1995;24:869. Letter.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
17. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds. Stroke. 1995; 26:885-890.
18. Tatlisumak T, Syrjälä M, Lindsberg P, Palotie A, Kaste M. FV-ARG-506-GLN-mutarion-associated resistance to activated protein C in ischemic stroke. J Stroke Cerebrovasc. 1995;5:192-196.
19. Albucher JF, Guiraud-Chaumeil B, Chollet F, Cadroy Y, Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. Stroke. 1996;27:766-767. Letter.
20. Catto A, Carter A, Grant PJ. Factor V Leiden mutation and completed stroke. Stroke. 1996;27:573. Letter.
21. Chimowitz M, Mansbach H, Schmaier A, Nichols W, Ginsburg D. Factor V mutation and cryptogenic stroke in the young. Stroke. 1996;27:188. Abstract.
22. 506→glutamine mutation. Stroke. 1996;27:1163-1166.
23. Ganesan V, Kelsey H, Cookson J, Osborn A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet. 1996;347:260. Letter.
24. Gross B, Senderowicz J, Cassel A, Zarfati D, Aghai E, Honigman S. Activated protein C resistance: a new etiology for cerebral thrombotic events during pregnancy and puerperium. Neurology. 1996;46:A478. Abstract.
25. Landi G, Cella E, Martinelli I, Tagliabue L, Mannucci PM, Zerbi D. Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke. 1996;27:1697-1698. Letter.
26. 506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis. 1996;7:684-688.
27. Press RD, Liu X-Y, Beamer N, Coull BM. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996;27:44-48.
28. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PTVM, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
29. Anzola GP. Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke. 1997;28:672. Letter.
30. Bontempo FA. Hassett AC, Faruki H, Steed DL, Webster MW, Makaroun MS. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25:271-276.
31. Disdier P, Weiller PJ, Donnet A, Aillaud MF. Neurological deficit after cerebral angiography and activated protein C resistance. Stroke. 1997: 28:672. Letter.
32. Kahn MJ, Scher C, Rozans M, Michaels RK, Leissinger C, Krause J. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease. Am J Hematol 1997;54:12-15.
33. Sanchez J, Román J, de la Torre MJ, Velasco F, Torres A. Low prevalence of the factor V Leiden among patients with ischemic stroke. Haemostasis. 1997;27:9-15.
34. Thorarensen O, Ryan S, Hunter J, Younkin DP. Factor V Leiden mutation: an unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis. Ann Neurol. 1997;42:372-375.
35. Schwartz SM, Siscovick DS, Longstreth WT Jr, Psaty BM, Beverly RK, Raghunathan TE, Lin D, Koepsell TD. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med. 1997;127:589-596.
36. Gardner MJ, Altman DG. Statistics With Confidence: Confidence Intervals and Statistical Guidelines. London, UK: BMJ; 1989.
37. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
38. Bridey F, Wolff M, Laissy JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost. 1995; 74:1382. Letter.
39. Brey RL, Coull BM. Cerebral venous thrombosis: role of activated protein C resistance and factor V gene mutation. Stroke. 1996;27:1719-1720. Editorial.
40. Deschiens M-A, Conard J, Herellou MH, Ameri A, Preter M, Chedru F, Samama MM, Bousser M-G. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724-1730.
41. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke. 1996;27:1731-1733.
42. Kimber TE, Lloyd JV, Brophy BP, Thompson PD. Cerebral venous sinus thrombosis associated with factor V gene mutation. J Neurol Neurosurg Psychiatry. 1996;61:204-205. Letter.
43. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393-394.
44. Sánchez del Rio M, Gómez-Tortosa E, Outeriño J. Cerebral venous thrombosis and activated protein C resistance. J Neurol. 1996;243:727-728. Letter.
45. Vuillier R, Moulin T, Tatu L, Rumbach L, Bertrand M-A. Isolated cortical vein thrombosis and activated protein C resistance. Stroke. 1996;27: 1440-1441. Letter.
46. Zuber M, Toulon P, Marnet L, Mas J-L. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
47. Siegert CEH, Smelt AHM, de Bruin TWA. Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis. Stroke. 1997;28:1291-1292. Letter.